News & Updates

SGLT2 inhibitor use helps reduce cardiovascular, renal deaths

Patients with diabetes mellitus, heart failure, or chronic kidney disease treated with sodium glucose co-transporter-2 inhibitors (SGLT2i) have a reduced risk of mortality from cardiovascular and renal causes, according to a study.

Semaglutide associated with reduced ICH risk in LVO treated with reperfusion therapy

Co-treatment with yoga plus camelina sativa powder improves outcomes in women with T2D

In women with type 2 diabetes (T2D), performing yoga in addition to supplementation with camelina sativa powder (CSP) delivers improvements in glycaemic indices, oxidative stress, and inflammatory markers, according to a study.

Okra supplementation may lower cardiovascular risk in prediabetes, T2D, diabetic nephropathy

Okra supplementation is beneficial to patients with prediabetes, type 2 diabetes (T2D), or diabetic nephropathy, conferring beneficial effects on lipid profile, diastolic BP, and inflammation markers, according to a systematic review and meta-analysis.

Original New Drug Application Approvals by US FDA (16-30 June 2026)

New drug applications approved by US FDA as of 16-30 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Consistent resistance training, limited sedentary behaviour help lower T2D risk

Engaging in resistance training over midlife and limiting sedentary behaviour have been shown to substantially lower the risk of type 2 diabetes (T2D) in a study.

Low vision-threatening DR incidence contrasts with high progression rate among Asians

The overall development of vision-threatening diabetic retinopathy (DR) among Asians with diabetes is low, although the incidence of progression to vision-threatening disease for those who already have DR is high, according to local research.

CGM plus virtual program improves HbA1c, weight in T2D adults with overweight/obesity

Continuous glucose monitoring (CGM) combined with a digital weight management program results in significant improvements in HbA1c, body weight, and other glucose metrics relative to usual care among adults with type 2 diabetes (T2D) and overweight or obesity, according to a study.